SOLO-3 Adds To AZ/MSD’s Lynparza’s Ovarian Cancer Success Tally But Impact Minimal
Executive Summary
Companies plan to discuss SOLO-3 data with the US FDA after Lynparza shows a benefit in third-line ovarian cancer, but commercial impact will be slight.
You may also be interested in...
Clinical Trials In Review: Big Hits And Misses In 2018
Scrip looks back at the studies released in 2018 and highlights trials that had a large impact, for better or worse.
Stellar Survival Data For AZ's Lynparza Hailed At ESMO
Clinicians and analysts have lauded spectacular results presented at ESMO from the SOLO-1 trial which strongly suggest that AstraZeneca's Lynparza should be the first-line maintenance treatment of choice for ovarian cancer patients with a BRCA mutation.
ADAURA Survival Boost For AZ’s Tagrisso
Impressive overall survival data from the Phase III ADAURA trial should boost both EGFR testing in non-small cell lung cancer, and sales of the blockbuster NSCLC therapy.